$14.86
0.10%
Nasdaq, Apr 21, 07:49 pm CET
ISIN
US15678C1027
Symbol
CBLL
Sector

Ceribell Stock price

$14.85
-5.63 27.48% 1M
-11.66 43.98% 6M
-11.04 42.64% YTD
-2.16 12.68% 1Y
-2.16 12.68% 3Y
-2.16 12.68% 5Y
-2.16 12.68% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.36 2.45%
ISIN
US15678C1027
Symbol
CBLL
Sector

Key metrics

Market capitalization $532.46m
Enterprise Value $360.05m
P/B ratio (TTM) P/B ratio 2.78
Cash position $194.37m
P/E forward negative
P/S forward 6.36
EV/Sales forward 4.30

Is Ceribell a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Ceribell Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Ceribell forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Ceribell forecast:

Buy
100%

Financial data from Ceribell

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
19 19
-
100%
- Direct Costs 2.30 2.30
-
12%
16 16
-
88%
- Selling and Administrative Expenses 25 25
-
134%
- Research and Development Expense 3.91 3.91
-
21%
-13 -13
-
-68%
- Depreciation and Amortization 0.36 0.36
-
2%
EBIT (Operating Income) EBIT -13 -13
-
-70%
Net Profit -13 -13
-
-68%

In millions USD.

Don't miss a Thing! We will send you all news about Ceribell directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ceribell Stock News

Neutral
GlobeNewsWire
6 days ago
SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next generation Ceribell Clarity™ algorithm for the detection of ...
Neutral
Seeking Alpha
about 2 months ago
CeriBell, Inc. (NASDAQ:CBLL ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Xingjuan Chao - President and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Robert Marcus - JPMorgan Chase & Co. Macauley Kilbane - William Blair & Company Joshua Jen...
Neutral
GlobeNewsWire
about 2 months ago
SUNNYVALE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2024.
More Ceribell News

Company Profile

Ceribell, Inc. is a commercial-stage medical technology company, which focuses on transforming the diagnosis and management of patients with serious neurological conditions. Its products include Point-of-Care EEG, which enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies, Clarity, an AI algorithm that interprets EEG in real-time, providing bedside alerts and continuous monitoring for status epilepticus, and EEG Portal, which makes it easy to remotely review EEG in real-time with pre-annotated EEG insights. The company was founded by Xing Juan Chao, Josef Parvizi, and Chris Chafe on August 29, 2014 and is headquartered in Sunnyvale, CA.

Head office United States
CEO Xing Chao
Employees 281
Website www.ceribell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today